Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 47

1.

High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone.

Zhan F, Barlogie B, Mulligan G, Shaughnessy JD Jr, Bryant B.

Blood. 2008 Jan 15;111(2):968-9. doi: 10.1182/blood-2007-10-119321. No abstract available.

PMID:
18182586
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature.

Chng WJ, Kuehl WM, Bergsagel PL, Fonseca R.

Leukemia. 2008 Feb;22(2):459-61. Epub 2007 Sep 6. No abstract available. Erratum in: Leukemia. 2008 Feb;22(2):462.

PMID:
17805328
[PubMed - indexed for MEDLINE]
3.

Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.

Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, Cottler-Fox M, Mohiuddin A, Alsayed Y, Tricot G, Bolejack V, Zangari M, Epstein J, Petty N, Steward D, Jenkins B, Gurley J, Sullivan E, Crowley J, Shaughnessy JD Jr.

Br J Haematol. 2007 Jul;138(2):176-85.

PMID:
17593024
[PubMed - indexed for MEDLINE]
4.

Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.

Shaughnessy JD Jr, Haessler J, van Rhee F, Anaissie E, Pineda-Roman M, Cottler-Fox M, Hollmig K, Zangari M, Mohiuddin A, Alsayed Y, Grazziutti M, Epstein J, Crowley J, Barlogie B.

Br J Haematol. 2007 Jun;137(6):530-6. Epub 2007 May 9.

PMID:
17489983
[PubMed - indexed for MEDLINE]
5.

Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.

Gómez-Benito M, Martinez-Lorenzo MJ, Anel A, Marzo I, Naval J.

Exp Cell Res. 2007 Jul 1;313(11):2378-88. Epub 2007 Mar 30.

PMID:
17462628
[PubMed - indexed for MEDLINE]
6.

CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms.

Zhan F, Colla S, Wu X, Chen B, Stewart JP, Kuehl WM, Barlogie B, Shaughnessy JD Jr.

Blood. 2007 Jun 1;109(11):4995-5001. Epub 2007 Feb 15.

PMID:
17303695
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Expression of the IFN-inducible p53-target gene TRIM22 is down-regulated during erythroid differentiation of human bone marrow.

Obad S, Olofsson T, Mechti N, Gullberg U, Drott K.

Leuk Res. 2007 Jul;31(7):995-1001. Epub 2007 Jan 24.

PMID:
17257675
[PubMed - indexed for MEDLINE]
8.

The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells.

Colla S, Zhan F, Xiong W, Wu X, Xu H, Stephens O, Yaccoby S, Epstein J, Barlogie B, Shaughnessy JD Jr.

Blood. 2007 May 15;109(10):4470-7. Epub 2007 Jan 25.

PMID:
17255354
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B.

Blood. 2007 Mar 15;109(6):2276-84. Epub 2006 Nov 14.

PMID:
17105813
[PubMed - indexed for MEDLINE]
Free Article
10.

Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.

Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Zangari M, Dhodapkar M, Shaughnessy JD Jr.

Blood. 2007 Feb 15;109(4):1692-700. Epub 2006 Oct 5.

PMID:
17023574
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

The p53-induced Wig-1 protein binds double-stranded RNAs with structural characteristics of siRNAs and miRNAs.

Méndez Vidal C, Prahl M, Wiman KG.

FEBS Lett. 2006 Aug 7;580(18):4401-8. Epub 2006 Jul 17.

PMID:
16844115
[PubMed - indexed for MEDLINE]
Free Article
12.

The molecular classification of multiple myeloma.

Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD Jr.

Blood. 2006 Sep 15;108(6):2020-8. Epub 2006 May 25.

PMID:
16728703
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation.

Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR, Hollmig K, Zangarri M, Pineda-Roman M, van Rhee F, Cavallo F, Burington B, Crowley J, Tricot G, Barlogie B, Shaughnessy JD Jr.

Blood. 2006 Sep 1;108(5):1724-32. Epub 2006 May 16.

PMID:
16705089
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

p53 and its downstream proteins as molecular targets of cancer.

Sun Y.

Mol Carcinog. 2006 Jun;45(6):409-15. Review.

PMID:
16652354
[PubMed - indexed for MEDLINE]
15.

High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients.

Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, Stewart JP, Zhan F, Khatry D, Protopopova M, Protopopov A, Sukhdeo K, Hanamura I, Stephens O, Barlogie B, Anderson KC, Chin L, Shaughnessy JD Jr, Brennan C, Depinho RA.

Cancer Cell. 2006 Apr;9(4):313-25.

PMID:
16616336
[PubMed - indexed for MEDLINE]
Free Article
16.

Thalidomide and hematopoietic-cell transplantation for multiple myeloma.

Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M, Crowley J.

N Engl J Med. 2006 Mar 9;354(10):1021-30.

PMID:
16525139
[PubMed - indexed for MEDLINE]
Free Article
17.

A global map of p53 transcription-factor binding sites in the human genome.

Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, Liu J, Zhao XD, Chew JL, Lee YL, Kuznetsov VA, Sung WK, Miller LD, Lim B, Liu ET, Yu Q, Ng HH, Ruan Y.

Cell. 2006 Jan 13;124(1):207-19.

PMID:
16413492
[PubMed - indexed for MEDLINE]
Free Article
18.

p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation.

Chang H, Qi C, Yi QL, Reece D, Stewart AK.

Blood. 2005 Jan 1;105(1):358-60. Epub 2004 Aug 31.

PMID:
15339849
[PubMed - indexed for MEDLINE]
Free Article
19.

p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis.

Kho PS, Wang Z, Zhuang L, Li Y, Chew JL, Ng HH, Liu ET, Yu Q.

J Biol Chem. 2004 May 14;279(20):21183-92. Epub 2004 Mar 11.

PMID:
15016801
[PubMed - indexed for MEDLINE]
Free Article
20.

Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs.

Cawley S, Bekiranov S, Ng HH, Kapranov P, Sekinger EA, Kampa D, Piccolboni A, Sementchenko V, Cheng J, Williams AJ, Wheeler R, Wong B, Drenkow J, Yamanaka M, Patel S, Brubaker S, Tammana H, Helt G, Struhl K, Gingeras TR.

Cell. 2004 Feb 20;116(4):499-509.

PMID:
14980218
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk